Valuation: Astellas Pharma Inc.

Market Cap 4,057B 25.54B 22.96B 21.43B 19.42B 36.46B 2,430B 36.69B 257B 100B 1,261B 95.88B 93.8B P/E 2027 *
10.4x
P/E 2028 * 11.2x
Enterprise Value 3,998B 25.16B 22.63B 21.11B 19.14B 35.93B 2,395B 36.15B 253B 98.94B 1,243B 94.48B 92.43B EV / Sales 2027 *
1.69x
EV / Sales 2028 * 1.62x
Free-Float
98.92%
Yield 2027 *
3.54%
Yield 2028 * 3.67%
1 day+4.15%
1 week+4.83%
Current month+1.55%
1 month+1.79%
3 months+10.01%
6 months-9.56%
Current year+12.59%
1 week 2,232
Extreme 2232
2,363.5
1 month 2,216
Extreme 2216
2,413
Current year 2,041
Extreme 2041
2,717
1 year 1,557.5
Extreme 1557.5
2,717
3 years 1,243.5
Extreme 1243.5
2,717
5 years 1,243.5
Extreme 1243.5
2,717
10 years 1,243.5
Extreme 1243.5
2,717
Manager TitleAgeSince
Chief Executive Officer 64 2023-02-09
Director of Finance/CFO 55 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 2023-02-09
Director/Board Member 64 2019-05-31
Director/Board Member 59 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+4.15%+4.83%+48.58%+23.67% 25.54B
+3.62%+1.68%+48.80%+98.41% 1,077B
+2.13%-1.76%+33.04%+61.88% 612B
+3.32%+4.47%+23.72%+91.59% 501B
+3.80%+3.21%+73.99%+41.69% 364B
+0.98%+6.12%+31.75%+48.44% 353B
+1.24%+5.44%+19.30%+42.34% 278B
+2.24%+5.55%-0.73%+14.40% 251B
+3.21%+3.15%+45.01%+49.99% 230B
+3.80%+4.56%+29.59%+97.73% 190B
Average +2.40%+1.80%+35.31%+57.01% 388.21B
Weighted average by Cap. +2.05%+1.57%+37.41%+69.07%

Financials

2027 *2028 *
Net sales 2,366B 14.89B 13.39B 12.5B 11.33B 21.26B 1,417B 21.4B 150B 58.56B 736B 55.92B 54.71B 2,203B 13.87B 12.47B 11.64B 10.55B 19.8B 1,320B 19.93B 140B 54.54B 685B 52.07B 50.95B
Net income 374B 2.36B 2.12B 1.98B 1.79B 3.37B 224B 3.39B 23.74B 9.27B 116B 8.85B 8.66B 344B 2.16B 1.95B 1.82B 1.65B 3.09B 206B 3.11B 21.79B 8.51B 107B 8.12B 7.95B
Net Debt -59.18B -373M -335M -313M -283M -532M -35.45B -535M -3.75B -1.46B -18.4B -1.4B -1.37B -481B -3.03B -2.72B -2.54B -2.3B -4.32B -288B -4.35B -30.47B -11.9B -149B -11.36B -11.11B
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26-10-15 JP¥2,356.50 +4.15% 9,143,400
26-10-14 JP¥2,262.50 -1.65% 4,701,100
26-10-13 JP¥2,300.50 +2.36% 4,347,300
26-10-09 JP¥2,247.50 -0.02% 5,898,400
26-10-08 JP¥2,248.00 -0.33% 5,458,800
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,262.50JPY
Average target price
2,529.29JPY
Spread / Average Target
+11.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.
  1. Stock Market
  2. Stocks
  3. 4503 Stock